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Use of the ROSE risk score for predicting mortality and 
cardiovascular events in adult patients at 7 and 30 days of syncope
Aplicación del puntaje de riesgo de la escala ROSE para predicción de mortalidad y 
desenlaces cardiovasculares mayores en pacientes adultos con síncope a 7 y 30 días
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Introduction: The use of the ROSE risk score after syncope provides 
the possibility of identifying patients at risk of death or other 
important adverse events after 30 days of admission to the emergency 
department.
Objective: To evaluate the performance of ROSE score in terms of 
mortality prediction and major adverse events at 7 and 30 days in 
adult patients with syncope admitted to the emergency department.
Materials and methods: A prospective cohort study in patients with 
syncope who were admitted to the emergency room was performed. 
An operational analysis of the predictive ability for detection 
of possible complications was done by calculating sensitivity, 
specificity, positive and negative predictive values and ROC curves.
Results: 60 patients were evaluated. An area under the curve 
for prediction of mortality or major outcome at 7 and 30 days of 
0.62 (95%CI: 0.45-0.78) was obtained, with sensitivity of 60%, 
specificity of 18.18%, PPV of 6.25% and NPV of 83%. 
Conclusion: ROSE score showed low sensitivity for predicting 
mortality or serious outcomes at 7 and 30 days. Its high negative 
predictive value makes it a useful prognostic tool in low risk 
patients.
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| Resumen |
Introducción. El puntaje de riesgo ROSE para síncope tiene la 
capacidad de identificar pacientes en riesgo de presentar mortalidad 
o cualquier otro desenlace adverso mayor a los 30 días de su ingreso 
a urgencias. 
Objetivo. Evaluar el rendimiento pronóstico del puntaje para 
predicción de mortalidad o desenlaces adversos mayores a 7 y 30 
días en pacientes adultos con síncope en el servicio de urgencias.
Materiales y métodos. Estudio de cohorte prospectivo en pacientes 
con síncope admitidos en urgencias. Se realizó un análisis operativo 
de la capacidad predictiva de detección de riesgo de complicaciones 
calculando sensibilidad, especificidad, valor predictivo positivo 
(VPP) y negativo (VPN) y curvas ROC. 
Resultados. Se evaluaron 60 pacientes en los que se obtuvo un área 
bajo la curva para predicción de mortalidad o desenlaces mayores, 
tanto a los 7 como a los 30 días, de 0.62 (IC95%: 0.45-0.78), con 
sensibilidad de 60%, especificidad de 18.18%, VPP de 6.25% y 
VPN de 83%.  
Conclusión. El puntaje ROSE mostró una sensibilidad baja para 
predicción de mortalidad o desenlaces serios mayores a 7 y 30 
días. Su alto valor predictivo negativo la hace una herramienta de 
pronóstico con utilidad en los pacientes de bajo riesgo.
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Introduction
Syncope is a major syndromic complex which supposes great 
challenge for diagnosis and therapy to health personnel in charge 
of patient care. The importance of the initial study, and short and 
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medium term risk assessment, lies in the difference between the 
relatively benign causes represented by vasovagal episodes and 
potentially fatal causes in a short period of time, such as conditions 
secondary to cardiovascular disease (1).
The economic burden, both direct and indirect, is highly relevant; 
this cost is primarily represented by intra-hospital expenses 
generated by the decision to hospitalize a patient with syncope, 
decision often unnecessarily taken by fear or lack of knowledge 
from health personnel about the life-threatening event. A new study 
finds that in a university hospital, 100% of patients admitted to the 
emergency room due to syncope were hospitalized (2); however, if 
early and medium term risk identification tools are used, lower costs 
can be achieved through outpatient management (3). 
Literature shows that multiple works have been developed on 
risk stratification scores, most of them obtained from the emergency 
department for short-term prognosis. Some of them, like the San 
Francisco Syncope Rule (SFSR), the Boston Syncope Rule, Oesil, 
Steps and Egsys, have shown deficiencies mainly when attempting 
external validation, exposing different results (4,5). This study 
evaluated the ROSE risk score diagnostic performance in a cohort 
of patients admitted for syncope to the emergency room.
Materials and methods
All patients older than 18, who attended the emergency rooms of 
Fundación Hospital San Carlos and Fundación Santafé de Bogotá due 
to syncope, between August 2013 and February 2014, were included. 
Syncope is defined as a transient altered state of consciousness and 
postural tone with spontaneous recovery without neurological deficit 
(except for amnesia after the event).
We excluded patients with loss or alteration of consciousness that 
was not secondary to transient cerebral hypoperfusion (consumption 
of alcohol or hypoglycemia), with head trauma presented before the 
syncopal episode, with a known history of epilepsy —typical seizure 
episode or prolonged postictal seen or described by witnesses— and 
persistent neurological deficit suggestive of acute vascular brain 
attack or transient cerebral ischemia. 
The study was approved by the ethics and research committees 
of the two institutions involved and patients signed an informed 
consent to participate. Follow-up was conducted through the review 
of medical records, if the patient was hospitalized during the follow-
up period or by telephone, if the patient had been discharged. A 
descriptive analysis of demographic characteristics, data specific to 
the syncopal event, history, physical examination and paraclinical 
exams requested at admission was made.
The following were considered as adverse outcomes: death, 
acute myocardial infarction, need for percutaneous or surgical 
coronary revascularization, severe aortic stenosis, aortic dissection, 
cardiac tamponade, pulmonary embolism, dilated cardiomyopathy 
with a left ventricular rejection fraction of <35%, diagnosis of 
major bradyarrhythmias and electrotherapy —pacemaker implant, 
pauses longer than three seconds, 2:1 AV Block, Type II Mobitz 
AV block, complete AV block, bradycardia under 30 bpm, 
alternating bundle branch block, pacemaker malfunction related 
to capture fault—, diagnosis of tachyarrhythmia —ventricular or 
sustained supraventricular tachyarrhythmia—, defibrillator implant, 
cardiac resynchronization therapy device implant, malfunction of 
cardioverter-defibrillator or cardiac resynchronization therapy 
device due to inadequate treatment of sustained ventricular 
arrhythmias, significant bleeding —need for transfusions, endoscopy 
requiring endoscopic treatment due to bleeding or need for surgical 
intervention due to bleeding—, lesions after the syncopal event that 
could affect life —head trauma, spinal fracture or long bones— and 
emergency readmission. 
The description of all the variables that make up the ROSE 
score was made for each patient: abnormality of electrocardiogram 
(presence of pathological Q waves, except for Lead III), presence or 
absence of anemia (HB ≤9 g/dl), bradycardia (heart frequency ≤50 
lpm), abnormal rectal examination when gastrointestinal bleeding 
was suspected, chest pain with syncope, abnormal brain natriuretic 
peptide (BNP) (≥300 pg/ml) and oxygen saturation abnormal to the 
environment (<94%).
All causes and major cardiovascular adverse events were considered 
as primary outcomes, while events such as mortality and independent 
major adverse events were considered as secondary outcomes.
A univariate analysis was conducted according to the nature of the 
variables: qualitative variables are presented with absolute numbers 
and proportions, while quantitative variables are presented with 
measures of central tendency (average) and statistical dispersion 
(standard deviation). A Kolmogorov–Smirnov test was performed 
to define the statistical tests that would be used for bivariate analysis 
and whether quantitative variables followed a normal distribution. 
For the prediction of the primary outcome at 7 and 30 days, the 
operating characteristics of the test were evaluated, sensitivity, 
specificity, positive predictive value (PPV) and negative predictive 
value (NPV). Data were analyzed through the SPSS V19 program.
Results
During the August 2013 - February 2014 period, 60 patients were 
selected. The average age was 66.47±20.3 and 56.7% (n=34) of the 
population were females. Demographic characteristics are shown 
in Table 1.
Table 1. Demographic characteristics of the study population.
Characteristic n (%)






Weight (, σ) 60.4 (10.2)
Size (, σ) 1.6 (0.08)
BMI 24.7 (3.7)
: average; σ: standard deviation; BMI: body mass index.
Source: Own elaboration based on the data obtained in the study.
In this population, 31.7% (n=19) had previous syncopal 
events; of these, 42% (n=8) registered a single syncopal event 
in the last six months, 15.8% (n=3) two episodes and 36.9% 
(n=7) three or more episodes. Other frequent antecedents were 
previous heart disease (25%) and heart failure diagnosis (21.7%) 
(Table 2).
The characteristics of the syncope episode commonly showed 
prodromal symptoms (51.7%) and dyspnea (36.7%). The average 
time elapsed between the time of syncope and consultation to the 
emergency department was three hours (RIQ=1.87-16.25). The 
average hospital stay for the study of syncope and management of 
complications was 8.9 days (0.5 to 60) (Table 3).
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Table 2. Medical history of the study population.
Medical history n (%)
Previous diagnosis of heart disease 15 (25.0)
Ischemic cardiopathology 9 (15.0)
Valvular heart disease 3 (5.0)
Dilated cardiomyopathy 5 (8.3)
Congenital heart disease 1 (1.7)
Diagnosis or clinical evidence of heart failure 13 (21.7)
Diagnosis or clinical evidence of peripheral arterial 
disease
5 (8.3)
Diagnosis or clinical evidence of chronic kidney 
disease
9 (15.0)
Previous diagnosis of stroke 3 (5.0)
Arrhythmias 4 (6.7)
Pacemaker 1 (1.7)
Implantable cardioverter defibrillator 1 (1.7)
Source: Own elaboration based on the data obtained in the study.
Table 3. Characteristics of the syncope episode of the study population.
Syncope characteristics n (%)
Dyspnea 22 (36.7)
Dehydration 1 (1.7)
Gastrointestinal bleeding 1 (1.7)
Chest pain 25 (41.7)
Syncope during exertion 1 (1.7)
Syncope in supine position 7 (11.7)
Syncope with high temperature 3 (5.0)
Post-trauma unconsciousness 17 (28.3)
Prodromal symptoms 31 (51.7)
Palpitations 8 (13.3)




Source: Own elaboration based on the data obtained in the study.
The physical exam at admission found mainly: systolic blood 
pressure of 125.1±23.3 mmHg, diastolic blood pressure of 72.5±13.7 
mmHg, heart rate of 68.5±17.7 bpm, respiratory rate of 19.6±9.5 
rpm and oxygen saturation of 90.05±12.4%. Electrocardiogram at 
admission found alterations in 76.7% (n=46).
The main abnormal electrocardiographic findings were: non-
specific changes in ST-T (54.3%), axis deviation (34.8%), sinus bradycardia 
(32.6%), left ventricular hypertrophy (30%), intraventricular 
conduction block (26%) and atrioventricular block (15%). 10.9% 
of patients had a pre-excitation pattern; the corrected mean of the 
QT interval was 412ms (normal). Within laboratory data taken on 
admission to the emergency unit, the obtained values of the variables 
that are part of the ROSE risk score were taken into account. 40% of 
the study population (n=24) showed values greater than or equal to 
BNP 300 pg/ml (abnormal) with a median of 524.5 pg/ml (225.75-
1727). Regarding hemoglobin, the average was 13.7 g/dl.
The incidence of the outcome at 7 and 30 days of follow up was 40% 
(n=24) and 8.3% (n=8), respectively (Table 4). 80% (n=40) of patients 
had a high risk score at admission, and 31.2% of them had an adverse 
outcome. All patients with a composite outcome between at 7 and 30 
days already had such outcome before 7 days had passed. The association 
evaluated with a Pearson’s chi-squared test was 1.522 with p=0.217.






Death - 2 (3.3)
AMI 8 (13.3) 3 (5.0)
Arrhythmias 10 (16.7) 2 (3.3)
FV 3 (5.0) 4 (6.7)
TV 2 (3.3) 2 (3.3)
Ventricular pause 1 (1.7) -
Ventricular pause 3 (5.0) -
Asystole 3 (5.0) -
Pulmonary embolism - 1 (1.7)
Stroke 1 (1.7) -
Intracranial hemorrhage 1 (1.7) -
Significant bleeding 3 (5.0) -
Transfusion 3 (5.0)  
Re-admission - 1 (1.7)
Sepsis 1 (1.7) -
CPR - 2 (3.3)
Percutaneous coronary intervention 4 (6.7) -
Pacemaker 5 (8.3) 2 (3.3)
CDI 2 (3.3) 2 (3.3)
Surgery of abdominal aortic aneurysm - 1 (1.7)
Coronary artery bypass graft - 1 (1.7)
Another cardiac surgery - 1 (1.7)
Vasopressor 4 (6.7) 1 (1.7)
Antiarrhythmic 6 (10.0) 3 (5.0)
ICU 19 (31.7) 1 (1.7)
Ischemia 10 (16.7) 2 (3.3)
Bradycardia 6 (10.0) -
Sinus pauses 1 (1.7) -
Mobitz II 1 (1.7) -
Third degree AV block 2 (3.3) -
Paroxysmal (SVT) 4 (6.7) -
TV 2 (3.3) 1 (1.7)
Source: Own elaboration based on the data obtained in the study.
Within components of ROSE risk score, 2 (3.3%) had fecal occult 
blood, 2 (3.3%) anemia (Hb≤9 g/dl), 24 chest pain (40%), 7 
(11.7%) Q waves in EGG, 24 (40.7%) BNP>300 pg/mL, 15 (25%) 
bradycardia (<50lpm), and 39 (65%) SaO2<94%.
There was no loss of follow-up at 7 or 30 days. For prediction 
of primary outcome —major, serious and death—, the ROSE 
risk score showed sensitivity, specificity, PPV and NPV of 60%, 
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18.18%, 6.25% and 83.33% respectively. The area under the ROC 
curve was 0.62 (95%CI: 0.45 to 0.78) (Figure 1 and 2).
Figure 1. Curve of operating characteristic of the receiver of the ROSE scale for 
composite outcome at 7 days. Source: Own elaboration based on the data 
obtained in the study.
Figure 2. Curve of operating characteristic of the receiver of the ROSE scale 
for composite outcome at 30 days. Source: Own elaboration based on the data 
obtained in the study.
Discussion
The main finding of this study is that the ROSE risk score did not have 
adequate performance for prognosis in this Colombian cohort to find 
sensitivity, specificity, and low VPP for mortality and major events. 
When comparing populations with syncope in this study with 
those of the original study by Reed et al. (6), it is possible to see 
that, in both, the average age was 65 and that patients had a higher 
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prevalence of cardiovascular comorbidities and similar risks of 
greater complications. A striking difference found in this research 
is a lower prevalence of previous history of syncopal episodes 
compared to the original study (32% vs. 43%). 
Previous history of syncope could represent more unidentified 
or previously unstudied cardiovascular comorbidity; however, as 
there are people with recurrent or frequent syncope, the neurally 
mediated mechanism or reflection is the most associated with these 
episodes and generates better prognosis and lower incidence of 
ominous events. In addition, patients present with higher prevalence 
of heart failure (21.7% vs. 5.1%) and high risk of sudden death; 
this important difference may explain the high prevalence (68%) 
of high BNP (>300 pg/ml) and why this population is sicker from a 
cardiovascular standpoint; however this is against adequate ROSE 
sensitivity rule.
The history of coronary artery disease —previous myocardial 
infarction— was also higher (15% vs. 10%), although it was not 
significant. In the original study, the cause of syncope was identified 
in the emergency department in 44% of cases, compared to what 
was found here, where most patients were hospitalized mainly due 
to uncertain diagnosis and short term prognosis.
76% of patients in this study had an abnormal electrocardiogram 
(ECG) on admission, ranging from subtle abnormalities to signs of 
significant structural heart disease; in contrast, the study of Reed et 
al. (6) found that 96% of patients had an ECG in sinus rhythm with 
no major abnormalities on admission. 
The follow-up after one year of the cohort of patients who 
underwent the ROSE score allowed finding that 52% of the events 
were manifested after the first 30 days of evaluation. Sensitivity 
decreased while specificity increased (71.6% and 71.1%, 
respectively), which is a typical behavior of a diagnostic test with 
greater statistical power (7) and which leads to infer that the scale 
loses performance as the index event progresses. 
It is important to assess the need for external validations since 
other scores found lower prognosis yield. Thus, e.g., Saccilotto 
et al. (8) conducted a systematic review that assessed 12 studies 
that used the San Francisco scale; in this study, the sensitivity 
and specificity of the scale varied considerably in relation to the 
original derivation —sensitivity of 87% and specificity of 52% in 
the systematic review, and sensitivity of 96% and specificity of 
62% in the derivation—. Similarly, the external validation of this 
scale showed distant values (sensitivity 89% and specificity 69%). 
As a consequence, it can be said there are specific factors of the 
population that make risk scales have a different behavior (9,10).
The high negative predictive value of the ROSE scale (83%) 
must be emphasized, which would make this score a useful tool in 
low-risk patients. All patients experiencing an outcome until day 7 
had no new events at 30 days, which reflects the need to broaden the 
sample of patients with syncope.
Prior to using BNP as a variable of cardiovascular adverse outcome 
with a risk score as ROSE, its usefulness as an independent risk factor 
in patients with syncope had already been evaluated. In the study of 
Reed et al. (11) the value of BNP for predicting adverse outcomes 
at three months in adult patients with syncope events was evaluated, 
finding that a value of 100 lpg/ml was more sensitive than that found 
in institutional risk prediction guides at three months of follow-up with 
similar specificity. It is likely that BNP is not useful for predicting 
outcomes in low risk groups, although no assessment of the issue is 
found. In this same study, more than 40% of patients had a BNP value 
greater than or equal to 300 pg/mL, representing a large sample of high 
risk patients for post-syncopal cardiovascular complications.
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D’Ascenzo et al. (12) evaluated 43 315 patients with syncope and 
determined that 10.4% had underlying cardiac abnormalities, being 
bradyarrhythmia the most common (4.8%); this is far exceeded 
in this study, where bradyarrhythmia was the third most frequent 
electrocardiographic finding (32.6%), preceded by axis deviation 
and changes in ST segment and T wave.
An important limitation when considering the use of a serum 
marker for damage or myocardial overload, as in the case of BNP in 
the assessment of the prognosis of patients with syncope, is based 
on the fact that BNP itself could be identified only in older patients, 
with higher prevalence of structural heart disease and heart failure, 
diseases that imply a worse prognosis and increased incidence 
of cardiovascular complications. However, this measurement 
represents a more objective marker of heart disease or cardiac 
involvement from another source compared to a medical history 
and, a much more subjective, physical examination.
Regarding the general limitations of the study, the most important 
is sample size, followed by the high variability reported in the 
reading of the electrocardiogram, which may vary depending on the 
observer’s experience. This makes a reliable standardized reading of 
these studies necessary, since the detection of electrocardiographic 
abnormalities allows the identification of patients with cardiogenic 
syncope, the main etiology associated with increased morbidity and 
mortality. Similarly, the follow-up time (30 days) can be considered 
minimal, because it limits the detection of long-term events.
Conclusions
Given the low calculated sensitivity and the small sample of patients, 
the ROSE risk score does not have a good diagnostic performance as 
a predictor of major cardiovascular outcomes and death at 30 days in 
the study population. Nevertheless, all patients with a low risk score 
(0) could be assessed on an outpatient basis given the high NPV.
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